Physician profile
Naureen Mirza
NPI 1386690535
$67,220.69
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $7,613 · 2021: $1,323 · 2022: $12K · 2023: $6,619 · 2024: $20.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,800 · Travel and Lodging: $1,457 · Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,800.00 |
| Travel and Lodging | $1,457.25 |
| Food and Beverage | $382.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $65,479.05 | 2019-2023 | |
| Horizon Therapeutics Plc | $1,311.34 | 2020-2021 | |
| Genzyme Corporation | $84.47 | 2019-2023 | |
| Amgen INC. | $81.09 | 2020-2023 | Enbrel, Otezla |
| Glaxosmithkline, LLC. | $61.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $50.68 | 2022 | |
| Organon LLC | $31.45 | 2023 | Renflexis, Hadlima |
| Lilly USA, LLC | $23.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.73 | 2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $19.14 | 2021 | |
| Sandoz INC. | $18.69 | 2023 | Hyrimoz |
| Genentech USA, INC. | $17.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naureen Mirza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.